CECOG Academy

www.cecog.org

 

CECOG Academy
Avatar

Modern Treatment Approaches in mPDAC: Overview of 1L/2L Options and Continuum of Care

By CECOG Academy FEATURING Gerald Prager
By CECOG Academy FEATURING Gerald Prager
0 views
July 22, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

08:44
Johnson & Johnson

Management and Proactive Care of Adverse Events Associated with Loca…

Feat. J. Sabari, A. Spira

Featured Video

02:58
Lilly Medical Affairs

A Heterogenous Disease with Varied Clinical Outcomes: HR+/HER2- MBC

Feat. J. O’Shaughnessy
Pancreatic Cancer
31:05
CECOG Academy

Modern Treatment Approaches in mPDAC: Overview of 1L/2L Options and …

Feat. G. Prager
23:51
CECOG Academy

2021 ASCO Paradigm Changing Updates on Pancreatic Ductal Adenocarcin…

Feat. T. Golan
35:20
CECOG Academy

2021 ASCO Abstracts Review in PAD: Palliative Care, Neoadjuvant Trea…

Feat. T. Golan, G. Prager, C. Yoo, E. Van Cutsem
28:06
CECOG Academy

Molecular Testing for Treatment Stratification on PDAC Patients: Whe…

Feat. C. Neuzillet, P. Hammel, M. Ikeda
30:57
CECOG Academy

PDAC Expert Panel Discussion: Differences in Clinical Practice, Turn…

Feat. C. Neuzillet, P. Hammel, M. Ikeda
23:53
CECOG Academy

mPAC Oligometastatic Disease Expert Discussion: Eligibility for 2nd …

Feat. T. Seufferlein, M. Falconi, K. Uesaka
30:28
CECOG Academy

Updates on mPAC: Is There a Target Group for Oligometastatic Disease…

Feat. T. Seufferlein
31:35
CECOG Academy

Expert Discussion on Resectable/Borderline-Resectable PAC: Gemcitabi…

Feat. G. Prager, T. Macarulla, E. Van Cutsem, C. Cheng Ean
23:59
CECOG Academy

Neoadjuvant Treatment Concepts for Resectable/Borderline-Resectable …

Feat. T. Macarulla
29:00
CECOG Academy

Expert Discussion on PRODIGE 24 Data on FOLFIRINOX vs. Gemcitabine a…

Feat. G. Prager, J. Taieb, H. Wasan, J. Oh Park
26:51
CECOG Academy

Adjuvant Treatment Options for PAC Patients: Who Should Receive FOLF…

Feat. J. Taieb